My Life, Our Future Research Repository — a rare disorder gets a rare opportunity
As a rare disorder, there is still a lot to learn about hemophilia. The hemophilia community in the United States has come together to improve care and advance hemophilia research though the My Life, Our Future (MLOF) project.
The MLOF Project: Phase One
The MLOF project was conducted from 2012 to 2018 through a partnership between ATHN, Bloodworks Northwest (BWNW), the National Hemophilia Foundation (NHF), and Bioverativ. The initiative was designed to engage the community to co-create a large repository of genotypic and phenotypic data about people with hemophilia, which could be used to accelerate research and advance care. As part of the process, more than 11,000 people received free genotyping, and more than 9,000 of those participants contributed their genetic data and biologic samples to create the MLOF Research Repository, the largest hemophilia scientific resource of its kind in the world.
The MLOF Research Repository
Since the completion of the collection phase, the repository has been incorporated into ATHN’s research portfolio, which enables ATHN to leverage its existing infrastructure to support related research. The biologic samples continue to be maintained by BWNW. ATHN, BWNW, and NHF continue our collaboration to ensure that research is supported and look forward to disseminating the results of the research to the community.
The MLOF Research Repository contains genotypic data and biologic samples from participants with hemophilia A and B, as well as potential and confirmed female genetic carriers who received care at one of more than 100 ATHN-affiliated hemophilia treatment centers across the United States. In 2017, scientists and researchers from around the county were invited to propose research projects utilizing the repository. Seven research projects were accepted based on scientific merit and level of benefit to those with bleeding disorders. All of these projects are currently underway. The MLOF partners look forward to sharing the research results with the community starting in 2021. Learn more about these Round One Approved Projects below.
The MLOF Project Enduring Contribution
Individuals who consented to participate in the MLOF Research Repository gave permission for whole genome sequencing and deposition into databases such as the National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI) database of Genotypes and Phenotypes (dbGaP). For many participants, blood was collected for RNA extraction, which is being performed through the National Heart, Lung, and Blood Institute (NHLBI) Transomics in Precision Medicine (TOPMed) program. The MLOF project information contained in these NIH-sponsored programs is now accessible to qualified scientists through application to NIH and is an enduring scientific contribution that will be leveraged to advance hemophilia care and research for many years to come.
Now, having seen the potential impact of research generated from this unparalleled repository of genetic data, ATHN, BWNW, and NHF are once again inviting proposals for research that can create dynamic improvements in patient care and address some of the most critical questions to change the outlook for hemophilia.
MLOF Research Repository Data Published in Frontiers in Medicine
The article, “HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset” by Joseph R. McGill, Vijaya L. Simhadri, and Zuben E. Sauna, is based on a research study aimed at providing estimates of inhibitor risk associated with the human leukocyte antigen (HLA) in patients with hemophilia A.
According to the article, there is wide recognition that genetic factors play a role in determining which patients develop inhibitors and which do not. However, identifying the genetic markers of immunogenicity is challenging.
This study used next-generation sequencing for high-resolution HLA Class II typing in patients with hemophilia A along with inhibitor prevalence reports from the MLOF Research Repository to calculate the odds ratios for inhibitor development based on various genetic factors. The researchers concluded that the HLA repertoire of a hemophilia A patient can be a risk factor for inhibitor development, representing a significant step toward better understanding of inhibitors and improving clinical care.
MLOF Research Repository – Round Two Approved Projects
Researcher: Thomas Howard, MD, PhD, University of Texas Rio Grande Valley School of Medicine
Project Description: Bleeding in hemophilia A (HA)—due to plasma factor (F)VIII deficiency—is arrested and prevented by infusing therapeutic FVIII proteins (tFVIIIs). But, tFVIIIs induce neutralizing-antibodies called “FVIII inhibitors” (FEIs) in ~20% of all HA patients (HAPs). These “FEI-patients” experience greater mortality/morbidity as bleeding can only be arrested/prevented with less safe/less effective therapeutics, which are also extremely expensive. Towards developing precision-diagnostics that accurately predict patient-specific FEI-formation, we will apply powerful new systems-biologic and trans-omic methodologies to a MLOF cohort of ~1,300 severe HAPs, and will analyze the data from these omic domains using a pedigree-based generalized linear mixed-model approach implemented in the statistical genetics package SOLAR, which was developed by our team.
Researcher: Shannon Meeks, MD, Emory University and Children's Healthcare of Atlanta
Project Description: Patients with hemophilia experience differing bleeding phenotypes that persist despite controlling for residual factor activity. Genetic alterations outside of F8/F9 may account for some of this phenotypic heterogeneity. Factor V (FV) and tissue factor pathway inhibitor (TFPI) are major determinates of thrombin generation in hemophilia, and thus genetic alterations that impact plasma levels of FV, FV-short, and TFPI may modulate bleeding in these patients. We aim to investigate the prevalence of F5 variants in patients with hemophilia and determine the impact of these variants on plasma FV, FV-short, thrombin generation, and TFPI levels as well as on clinical bleeding phenotype.
Researcher: Amanda B. Payne, PhD, MPH, Centers for Disease Control and Prevention
Project Description: Inhibitors are the most important treatment-related complication among persons with hemophilia A (PWH). However, to date, inhibitor risk prediction models have been either of limited in usefulness among untreated PWH or not validated among large numbers of PWH. This project aims to evaluate the performance of inhibitor risk prediction models, that rely on genetic information, among PWH enrolled in the MLOF Research Repository by examining receiver operating characteristics curve metrics. Understanding who may be at highest risk of inhibitor development could help guide treatment decisions, particularly the use of factor versus non-factor products.
Researcher: Johnson Liu, MD, Maine Medical Center
Project Description: Variability in bleeding is well described in hemophilia, but the potential mitigating role of prothrombotic gene variants is unclear. Prior suggestive research was hampered by small sample sizes, but we propose using the MLOF Research Repository, the world’s largest repository of data including whole genome sequencing from hemophilia patients. We hypothesize that co-inheritance of prothrombotic gene variants modulates bleeding severity in patients with a defined genotype. Our specific aims: (1) We will test a panel of prothrombotic gene variants in modulating bleeding phenotype; (2) We will evaluate the role of Von Willebrand Factor gene variants in modulating bleeding phenotype.
MLOF Research Repository – Round One Approved Projects
Mathematical Immune Model for Predication of Factor VIII Inhibitor Development and Its Impact on Clinical Outcome of Treatment for Hemophilia A Patients
Researchers: Zuben Sauna, PhD and Hong Yang, PhD, Center for Biologics Evaluation and Research, Food & Drug Administration, Department of Health and Human Services
Project Description: About 30% of hemophilia A patients treated with Factor VIII develop anti‐drug‐antibodies. We are trying to understand why some patients develop anti‐drug‐antibodies while others do not. We will use the information obtained from the My Life, Our Future and the American Thrombosis and Hemostasis Network to develop a comprehensive mathematical model for immune responses to therapeutic proteins. Such a model, once validated, can be used while evaluating new FVIII‐drugs to project the immunogenicity‐risk in the larger population once drugs are marketed or to plan the appropriate treatment for newly diagnosed patients. Eventually it may spur the development of specific products for different classes of hemophilia A patients.
Researcher: Ming Lim, MBBCH, MS, University of Utah
Project Description: Using the MLOF Research Repository and the ATHNdataset as a source population for non-severe hemophilia A patients, this study will attempt to determine the association between inhibitor development and F8 mutation in non-severe hemophilia A patients. Prior studies in Europe have demonstrated the potential of F8 genotyping to estimate individualized risks of inhibitor formation for those mutations with sufficient data. Specific US data on risk of inhibitor formation has immediate clinical relevance as it can help contribute to decision-making on the management of elective procedures in NSHA patients.
Researcher: Steven Pipe, MD, University of Michigan
Project Description: Patients with severe hemophilia A, factor VIII (FVIII) deficiency, exhibit variability in FVIII half-life, creating a risk for bleeding and susceptibility to progressive joint disease. These variabilities can have a profound effect on the amount of factor they use and their clinical outcomes, yet little is known about the factors that determine this variability. The ATHN/MLOF clinical database and biorepository will allow us to investigate the genetic basis for these marked inter-individual variations through analysis of a patient’s entire genetic sequence. This may in turn inform bioengineering strategies to extend the half-life of FVIII therapeutics and perhaps highlight ethnic variability and inhibitor risk.
Researcher: Kathleen Pratt, PhD, Uniformed Services University
Project Description: Both the hemophilia-causing FVIII mutation and a family history of inhibitors contribute to inhibitor risk, strongly indicating that still-unidentified genetic factors contribute to this risk. We propose to utilize the MLOF database to analyze specific immune-response-associated DNA regions to find genetic variations that contribute to inhibitor risk. Patients with lower-level immune responses to FVIII, including non-inhibitory anti-FVIII antibodies, are considered to have “partial immune tolerance” to FVIII. We wish to determine what causes some patients to develop high-titer responses while other antibody responses remain clinically insignificant. Our goal is to discover novel therapeutic targets to lower inhibitor incidences.
Researcher: Rodney Camire, PhD, Children’s Hospital of Philadelphia
Project Description: Following injury, the body rapidly responds to stop bleeding. This process involves cells in the blood and proteins (coagulation factors) that work to form a blood clot. For some people, these factors are reduced/missing and they have an increased risk of bleeding, a disorder called hemophilia A or B. Often the severity of bleeding among hemophilia patients with the same factor levels is variable. The goal of our study is to measure a protein in blood (TFPI) that works to prevent too much blood clotting and determine if changes in its levels modify the bleeding patterns in severe hemophilia.
Researcher: Jill Johnsen, MD, Bloodworks Northwest Research Institute
Project Description: Female carriers of hemophilia have excessive bleeding that is not well explained by their clotting factor levels. We propose to study carriers and male relatives in My Life, Our Future. We will study specific DNA changes for effects on gene expression that can be missed by routine testing and determine if those changes are associated with bleeding. We will also study if low levels of another blood clotting protein, von Willebrand factor, are associated with bleeding in carriers. We hope these studies will help us care for at-risk female carriers in the future.
Researcher: Tim Harris, PhD, DSc, Bioverativ Therapeutics
Project Description: Development of inhibitors remains a major complication of replacement therapy in hemophilia. While factor mutation type may largely contribute to the risk of inhibitor development, the underlying basis for why some patients develop inhibitors, while others do not, remains poorly understood. We aim to conduct an analysis of gene burden using data (genetic and medical) from My Life, Our Future to elucidate which genes play a role in inhibitor development. This includes investigation of Fc receptor variants, which have been reported to impact the immune response to FVIII. Further correlation of findings may involve characterization of antibodies using research repository samples.
If you have any questions about the MLOF Research Repository, contact email@example.com.